Mumbai, Nov. 25 -- The product is the generic equivalent of Calan SR Extended-Release Tablets.
The medication is used for the management of high blood pressure, helping reduce the risk of cardiovascular complications such as strokes and heart attacks.
Zydus will manufacture the approved product at its facility in Baddi, Himachal Pradesh.
According to IQVIA MAT September 2025 data, Verapamil Hydrochloride ER Tablets recorded annual sales of $ 24.5 million in the US market.
With this approval, Zydus' cumulative tally rises to 428 approvals. The group has filed 487 ANDAs since it began the filing process in FY 2003-04.
The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives...